Skip to main content

Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.

Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F

Publication: Clin Cancer Res (2009) • Vol 15 • Page 267-73PMID: 19118054View on PubMed

Purpose

The paper investigated the effects of storage and inter-reader, intra-reader, and inter-laboratory variability on the enumeration of circulating endothelial cells (CECs) and progenitors (CEPs) of fresh and frozen blood specimens using a novel flow cytometry method.

Conclusion

Flow cytometric analysis showed significantly more CECs and CEPs in blood collected from patients diagnosed with a solid malignant tumor compared to healthy volunteers, but the number of CECs and CEPs recovered was influenced by cancer type. Blood collected from healthy individuals had a higher percentage of apoptotic/necrotic cells compared to blood specimens collected from cancer patients regardless of tumor type. Intra-reader variability and inter-reader variability, as well as variability attributable to room temperature or frozen storage were very low for CECs recovered from fresh specimens stored up to 72 h and frozen specimens stored >6 months.

Studies (1)

Purpose

This study investigated the effects of storage and inter-reader, intra-reader, and inter-laboratory variability on the enumeration of CECs and CEPs of fresh and frozen specimens using a novel flow cytometry method. Peripheral blood was collected in EDTA tubes from 37 healthy volunteers (age range, 26-50) and 78 patients diagnosed with a solid malignant tumor (age range, 42-61). The first 3 mL of blood drawn from each individual was discarded to avoid endothelial cell contamination from the venipuncture. Freshly collected peripheral blood specimens were analyzed the same day as collection or stored for 24, 48, and 72 h prior to analysis.  Effects of freezing and frozen storage were also assessed using blood specimens that were collected in tubes containing sodium citrate, processed to isolate white cells by ficoll gradient, subjected to controlled rate freezing, and stored in liquid nitrogen until shipped (<7 days). Frozen cells were thawed in storage media after 0, 2, 7, and 14 days of storage, and analyzed within 60 min. Cells were incubated with nuclear stains (Syto16 and 7-AAD) and extracellular stains (CD45 to exclude hematopoietic cells, CD133 for progenitor cells, and endothelial cell markers CD31 and CD146) and analyzed by flow cytometry. Low Syto16/positive 7-AAD cells were designated as necrotic, low Syto16/negative 7-AAD cells as apoptotic, and bright Syto16/negative 7-AAD cells as viable. A fresh and frozen specimen was evaluated in triplicate by a single operator to assess intra-reader variability and by three different operators to assess inter-reader variability. Duplicate frozen specimens were shipped from Houston to two laboratories in Milan and analyzed after >6 months of storage (conditions not provided). Cells sorted by flow cytometry were fixed with 2.5% glutaraldehyde and analyzed by electron microscopy and RNA was isolated using the QIAmp RNA blood mini kit, cDNA transcribed using the High-Capacity cDNA Reverse Transcription kit, and VE-cadherin expression analyzed on a sequence analyzer.

Summary of Findings

Flow cytometric analysis showed significantly more CECs and CEPS in blood from cancer patients compared to healthy volunteers (951 ± 1,876 CECs/mL versus 140 ± 171 CECs/mL, P < 0.0001 and 429 ± 507 CEPs/mL versus 181 ± 167 CEPs/mL, P = 0.00019, respectively).  A significantly higher percentage of CECs were apoptotic/necrotic in healthy volunteers (77 ± 14%) compared to cancer patients (43 ± 23%; P< 0.0001). While the total number of CECs and CEPs recovered from non-small cell lung cancer, small cell lung cancer, and melanoma patients was similar to healthy volunteers, the percentage of apoptotic CECs was significantly different among the different tumor types (P<.0001, P<.0001, and P<.001, respectively). However, patients with locally advanced breast cancer and metastatic breast cancer had significantly more CECs than healthy volunteers (P<.01 and P<.0001, respectively), a lower percentage of apoptotic CECs (P<.0001 each), and more CEPs (P<.01 and P<.0001, respectively). RT-PCR analysis of peripheral blood collected from healthy volunteers for VE-cadherin mRNA levels revealed 6 ± 2 copies per 1,000 cells and the average number of CECs recovered after sorting represented 30 ± 7% of the VE-cadherin expression.

Intra-reader and inter-reader variability were very low for CECs recovered from fresh specimens (CV= 4 ± 4%, CV=17 ± 4%, respectively) and from frozen specimens (12 ± 8%, 16 ± 10%, respectively). Variability attributable to storage duration was also very low for CECs recovered from fresh (17 ± 7% over 72 h) and frozen specimens (26 ± 16% over 0-14 days in liquid nitrogen). Mean CEP recovery (based upon the number of CEPs obtained from specimens analyzed the same day as collection) from specimens stored frozen for 2, 7, and 14 days was 71 ± 18% and mean CEP viability was 81 ± 12%. Duplicate frozen specimens sent from Houston to two laboratories in Milan analyzed after >6 months of storage showed low CEP variability (CV=22 ± 12%).

  • Biospecimens

    FluidBlood
  • Preservation Types

    FrozenOther Preservative
  • Diagnoses

    NeoplasticCarcinoma
    Normal
  • Platforms

    Cell count/volumeFlow cytometry
    Cell count/volumeElectron microscopy
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Locally advanced breast cancer
    Melanoma
    Metastatic breast cancer
    Non-small cell lung cancer
    Small cell lung cancer
    StorageStorage duration
    0 days
    14 days
    2 days
    7 days
    StorageTime at room temperature
    24 h
    48 h
    72 h
    Real-time qRT-PCR SpecificTargeted nucleic acid
    E-cadherin
    Flow cytometry SpecificTargeted peptide/protein
    7-AAD
    CD133
    CD146
    CD31
    CD45
    Syto16